ClinicalTrials.gg
CompletedNCT05754775K-Direct1Updated Aug 6, 2025

Remission of Type 2 Diabetes Via Calorie Restriction

An interventional study of Calorie restriction via total food replacement in Type 2 Diabetes and Obesity, Morbid, sponsored by Yeouido St. Mary's Hospital. Completed at 1 site in South Korea. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Yeouido St. Mary's Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Enrollment
452nd of 493
27 · median 174
Started
2023
with 30 others
No phase
48 of 571
8 open now
Registered
455th of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 452nd largest by enrollment of the 493 interventional ones that give a count, is one of 31 that started in 2023, is one of 48 with no phase, and was the 455th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The primary purpose was to evaluate the efficacy of Korean low-calorie diet for obese adult patients with type 2 diabetes with a body mass index of 25 kg/m2 or higher.

Read the detailed description

Previous studies reporting the natural course of type 2 diabetes generally reported progressive worsening of the disease. However, several recent studies suggested that significant weight loss induced by an very-low calorie diet could lead to the improvement in glycemic control that enough to drug discontinuation. Considering that improvement in diabetes is not permanent and hyperglycemia may recur, American and European expert groups define and express the improvement of diabetes as "remission".

In several studies in the Western contries, remission was confimed in patients who achieved significant weight loss with a daily intake of less than 800 kcal consisting of powder with high protein ingredients. When 11 patients with the disease were given only 600 kcal daily for 8 weeks, fasting blood glucose significantly decreased within 7 days. (Diabetologia 2011; 54: 2506-14). In a follow-up study, dietary intervention for 8 weeks was applied to 30 patients, about 40% of the patients showed remission of diabetes. (Diabetes Care 2016; 39: 158-65).

Based on this small study, a primary care-based research group in the United Kingdom recruited obese diabetic patients from private clinics across the country and evaluated the diabetic remission effect of a very-low caloric diet in a total of 306 patients. In this study, 46% of the intervention group and 4% of the non-intervention group reported remission, confirming a significant difference in remission rates. Patients who achieved more weight loss in the intervention group had higher remission rates, with a remission rate of 57% for patients who lost 10 to 15 kg and a remission rate of 86% for patients who lost more than 15 kg. (Lancet 2018; 391: 541-51).

On the other hand, in Korea, a study has been conducted using a Korean traditional foods designed by clinical nutritionists for diabetic patients that delivers to home. When continuous blood glucose measurement was performed while the special diet program was provided for 2 weeks, mean blood glucose and estimated glycated hemoglobin during the treatment diet period decreased compared to the free food period. The effect of the Korean-style diabetic diet was thought to be mainly due to the decrease in blood glucose levels after meals (J Korean Diabetes 2020;21:46-54).

In previous studies, total food replacement for calorie restriction was only attempted in the form of powder. In the case of the Korean diet, it contains a sufficient amount of dietary fiber and has the advantage of maintaining appropriate clinical nutrition therapy by providing various textures and tastes. Therefore, the investigators planned a clinical study to induce remission with a low-calorie diet using the Korean diet as a meal replacement therapy for calorie restriction in Korean patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
  • Obesity, Morbid
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes

    • If you have been diagnosed with diabetes within the last 6 years and have been treated for diabetes for more than 3 months
    • was measured as less than 9% without insulin treatment for the last 3 months
  • of 23kg/m2 or more

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Target organ failure such as heart failure, liver failure, kidney failure, and chronic obstructive disease
  • History of cardiovascular disease and cancer and current treatment
  • Acute infection or acute treatment requiring hospitalization such as surgery within the last 3 months
  • Any medications that may affect blood sugar within the last 6 months
  • Food allergies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Low-calorie diet

    Korean low-calorie diet for type 2 diabetes

    Behavioral: Calorie restriction via total food replacement

Interventions

  • BehavioralCalorie restriction via total food replacement

    Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.

06

What researchers measure

Primary outcomes

  1. Remission

    It is defined as a case where the HbA1c measured at the end of the 12-week intervention after stopping the drug was less than 6.5%.

    Time frame: The glycated hemoglobin level in percentage measured 12 weeks after the study screening date was used.

Secondary outcomes

  1. Weight loss

    It is defined as the change in body weight before and after the intervention.

    Time frame: The body weight in kilograms measured 12 weeks after the study screening date was used.

07

Study locations

1 site
  • Yeouido St. Mary's Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Apr 2024, 10 months.

Of 2,072 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 10 months is below that.

Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Mar 6, 2023
StartActual
Jun 1, 2023
Primary completionActual
Apr 30, 2024
CompletionActual
Apr 30, 2024
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05754775
Lead sponsor
Yeouido St. Mary's Hospital
Collaborators
Abbott
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Jun 1, 2023
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Last update
Aug 6, 2025

Study contacts

Hyuk-Sang Kwon
principal investigator · Yeouido St. Mary's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion